Form 4: Bristol-Myers Squibb SVP and Controller, Phil M. Holzer, Reports Changes in Beneficial Ownership

Phil M. Holzer, SVP and Controller of Bristol-Myers Squibb, filed a Form 4 detailing transactions involving common stock and derivative securities, including vesting of market share units and performance shares.

Summary

• On March 10, 2025, Phil M. Holzer, SVP and Controller of Bristol-Myers Squibb (BMY), reported changes in beneficial ownership of company stock.
• The transactions involved the vesting of market share units and performance shares, as well as the withholding of shares for tax payments.
• Holzer acquired and disposed of common stock, resulting in adjustments to his directly held shares.
• He also acquired market share units that convert into common stock based on performance factors related to stock price and shareholder return.
• The reported transactions reflect the vesting of awards granted in previous years, including 2021, 2022 and 2023.
• Some market share units cliff vest on the third anniversary of the grant date, subject to performance certification by the Board.
• Performance shares earned under the 2022-2024 Long-Term Performance Award were distributed.
• The filing indicates Holzer's direct ownership of 14,967 shares of common stock and 7,368 performance shares.

Sentiment

Score: 7

Explanation: The document reflects routine executive compensation adjustments, suggesting stable company performance and alignment of management interests with shareholders. The sentiment is neutral to slightly positive.

Positives

• The vesting of market share units and performance shares suggests that the company is meeting certain performance targets.
• The executive's continued holding of a significant number of shares indicates confidence in the company's future performance.

Negatives

• The sale of shares to cover tax obligations reduces the executive's holdings, although this is a common practice.

Risks

• The value of market share units is tied to the company's stock price and total shareholder return, which are subject to market fluctuations.
• The performance-based vesting of shares introduces uncertainty, as the actual payout depends on the company's performance against pre-defined metrics.

Future Outlook

The document indicates future vesting dates for market share units and performance shares, contingent on the company's performance and board certification.

Industry Context

Executive compensation in the pharmaceutical industry often includes stock options and performance-based equity awards to align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock-based compensation is a common practice among large pharmaceutical companies like Johnson & Johnson (JNJ), Pfizer (PFE), and Merck (MRK).
• These companies often use a mix of stock options, restricted stock units, and performance shares to incentivize executives.
• The specific terms of these awards, such as vesting schedules and performance metrics, vary depending on the company's compensation philosophy and strategic goals.

Stakeholder Impact

• Shareholders are impacted by the dilution effect of stock-based compensation.
• Employees, particularly executives, are incentivized to improve company performance through equity-based awards.

Next Steps

• Continued monitoring of executive compensation filings to assess alignment with company performance.
• Tracking the vesting of future market share units and performance shares to evaluate the company's progress against its strategic goals.

Key Dates